Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice

Journal of Controlled Release

Volumn 140, Issue 1, 2009, Pages 12-17

  Katsumi, Hidemasa ^a   Nishikawa, Makiya ^a   Yasui, Hiroyuki ^b   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Hepatic targeting; Macromolecules; Nitric oxide; Nitric oxide donor; S nitrosothiols

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOVINE SERUM ALBUMINS; COVALENTLY BOUND; ELECTRON SPIN RESONANCE; HEPATIC INJURY; HEPATIC TARGETING; INTRAVENOUS INJECTIONS; ISCHEMIA/REPERFUSION; LIVER CELLS; MOUSE LIVER; MOUSE MODELS; NITRIC OXIDE DONOR; NITROSO; NITROSOTHIOLS; NO MOLECULE; PORTAL VEINS; REPERFUSION; S-NITROSOTHIOLS; SERUM LEVELS;

LIVER; MACROMOLECULES; NITRIC OXIDE; PLANTS (BOTANY); SPIN DYNAMICS; SULFUR COMPOUNDS; SUPRAMOLECULAR CHEMISTRY;

BODY FLUIDS;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOVINE SERUM ALBUMIN; DRUG CARRIER; GALACTOSE; INDIUM 111; MANNOSE; NITRATE; NITRIC OXIDE; NITRITE; S NITROSOTHIOL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TISSUE LEVEL; ELECTRON SPIN RESONANCE; GLYCOSYLATION; LIVER INJURY; LIVER ISCHEMIA; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHYSICAL CHEMISTRY; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; REPERFUSION INJURY; SYNTHESIS;

ANIMALS; CATTLE; LIVER; MALE; MANNOSE; MICE; MICE, INBRED STRAINS; NITRIC OXIDE; NITRIC OXIDE DONORS; REPERFUSION INJURY; S-NITROSOTHIOLS; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE;

EID: 70349843440     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.07.013     Document Type: Article

References (40)

1. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
2. Radomski M.W., Palmer R.M., and Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 92 (1987) 181-187
3. Kurose I., Wolf R., Grisham M.B., and Granger D.N. Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ. Res. 74 (1994) 376-382
4. Gryglewski R.J., Palmer R.M., and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320 (1986) 454-456
5. Rodenas J., Mitjavila M.T., and Carbonell T. Nitric oxide inhibits superoxide production by inflammatory polymorphonuclear leukocytes. Am. J. Physiol. 274 (1998) C827-830
6. Kanwar S., Tepperman B.L., Payne D., Sutherland L.R., and Kubes P. Time course of nitric oxide production and epithelial dysfunction during ischemia/reperfusion of the feline small intestine. Circ. Shock 42 (1994) 135-140
7. Jaeschke H. Reactive oxygen and ischemia/reperfusion injury of the liver. Chem. Biol. Interact. 79 (1991) 115-136
8. Jaeschke H., Bautista A.P., Spolarics Z., and Spitzer J.J. Superoxide generation by Kupffer cells and priming neutrophils during reperfusion after hepatic ischemia. Free Radic. Res. Commun. 15 (1991) 277-284
9. Katsumi H., Nishikawa M., and Hashida M. Development of nitric oxide donors for the treatment of cardiovascular diseases. Cardiovasc. Hematol. Agents Med. Chem. 5 3 (2007) 204-208
10. Miller M.R., and Megson I.L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 151 3 (2007) 305-321
11. Jaworski K., Kinard F., Goldstein D., Holvoet P., Trouet A., Schneider Y.J., and Remacle C. S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells. Eur. J. Pharmacol. 425 (2001) 11-19
12. Liu P., Xu B., Hock C.E., Nagele R., Sun F.F., and Wong P.Y. NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Am. J. Physiol. 275 (1998) H2191-2198
13. Quintana A.B., Rodriguez J.V., Lenzi H.L., and Guibert E.E. Effect of S-Nitrosoglutathione (GSNO) added to the University of Wisconsin Solution (UW): mast cell degranulation during normothermic reperfusion. Ann. Hepatol. 3 (2004) 113
14. Richardson G., and Benjamin N. Potential therapeutic uses for S-nitrosothiols. Clin. Sci. (Lond.) 102 (2002) 99-105
15. Katsumi H., Nishikawa M., Yamashita F., and Hashida M. Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J. Pharmacol. Exp. Ther. 314 (2005) 1117-1124
16. Katsumi H., Nishikawa M., Yamashita F., and Hashida M. Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating blood in mice. Transplantation 85 2 (2008) 264-269
17. Nishikawa M. Development of cell-specific targeting systems for drugs and genes. Biol. Pharm. Bull. 28 2 (2005) 195-200
18. Katsumi H., Nishikawa M., Ma S.F., Yamashita F., and Hashida M. Physicochemical, tissue distribution, and vasodilation characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo. J. Pharm. Sci. 93 (2004) 2343-2352
19. Yabe Y., Kobayashi N., Nishikawa M., Mihara K., Yamashita F., Takakura Y., and Hashida M. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm. Res. 19 12 (2002) 1815-1821
20. Scott T.A., and Melvin E.H. The determination of dextran with anthrone. Anal. Chem. 25 (1953) 1656-1661
21. Duncan R.J., Weston P.D., and Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins and its use in the preparation of conjugates for immunoassay. Anal. Biochem. 132 (1983) 68-73
22. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
23. Saville B. A scheme for the colorimetric determination of microgram amounts of thiols. Analyst 83 (1958) 670-672
24. Hnatowich D.J., Layne W.W., and Childs R.L. The preparation and labeling of DTPA-coupled albumin. Int. J. Appl. Radiat. Isot. 33 (1982) 327-332
25. Kirima K., Tsuchiya K., Sei H., Hasegawa T., Shikishima M., Motobayashi Y., Morita K., Yoshizumi M., and Tamaki T. Evaluation of systemic blood NO dynamics by EPR spectroscopy: HbNO as an endogenous index of NO. Am. J. Physiol, Heart Circ. Physiol. 285 2 (2003) H589-596
26. O Keeffe D.H., Ebel R.E., and Peterson J.A. Studies of the oxygen binding site of cytochrome P-450. Nitric oxide as a spin-label probe. J. Biol. Chem. 253 10 (1978) 3509-3516
27. Yabe Y., Kobayashi N., Nishihashi T., Takahashi R., Nishikawa M., Takakura Y., and Hashida M. Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. J. Pharmacol. Exp. Ther. 298 (2001) 894-899
28. Mihara K., Oka Y., Sawai K., Takakura Y., and Hashida M. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J. Drug Target. 2 (1994) 317-321
29. Nishikawa M., Hirabayashi H., Takakura Y., and Hashida M. Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharm. Res. 12 2 (1995) 209-214
30. Ogawara K., Hasegawa S., Nishikawa M., Takakura Y., and Hashida M. Pharmacokinetic evaluation of mannosylated bovine serum albumin as a liver cell-specific carrier: quantitative comparison with other hepatotropic ligands. J. Drug Target. 6 5 (1999) 349-360
31. Chen T., Zamora R., Zuckerbraun B., and Billiar T.R. Role of nitric oxide in liver injury. Curr. Mol. Med. 3 6 (2003) 519-526
32. Takakura Y., Masuda S., Tokuda H., Nishikawa M., and Hashida M. Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochem. Pharmacol. 47 5 (1994) 853-858
33. Nishikawa M., Miyazaki C., Yamashita F., Takakura Y., and Hashida M. Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am. J. Physiol. 268 5 (1995) G849-856
34. Yabe Y., Nishikawa M., Tamada A., Takakura Y., and Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 289 2 (1999) 1176-1184
35. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
36. Kosonen O., Kankaanranta H., Uotila J., and Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur. J. Pharmacol. 394 (2000) 149-156
37. Lee V.G., Johnson M.L., Baust J., Laubach V.E., Watkins S.C., and Billiar T.R. The roles of iNOS in liver ischemia-reperfusion injury. Shock 16 (2001) 355-360
38. Naito Y., Takagi T., Ichikawa H., Tomatsuri N., Kuroda M., Isozaki Y., Katada K., Uchiyama K., Kokura S., Yoshida N., Okanoue T., and Yoshikawa T. A novel potent inhibitor of inducible nitric oxide inhibitor, ONO-1714, reduces intestinal ischemia-reperfusion injury in rats. Nitric Oxide 10 (2004) 170-177
39. Ikebe N., Akaike T., Miyamoto Y., Hayashida K., Yoshitake J., Ogawa M., and Maeda H. Protective effect of S-nitrosylated alpha(1)-protease inhibitor on hepatic ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 295 (2000) 904-911
40. Ishima Y., Sawa T., Kragh H.U., Miyamoto Y., Matsushita S., Akaike T., and Otagiri M. S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties. J. Pharmacol. Exp. Ther. 320 (2007) 969-977